# Freeze of Gait Market > Freeze of Gait Market Research Report Information By Type (Oral Dopaminergic Medication, Wearable and Walking Aid Devices, Deep Brain Stimulation, Others), End User (Hospitals, Clinics, Others) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.86% - **2024:** $ 1.28 Billion - **2025:** $ 1.34 Billion - **2035:** $ 2.16 Billion - **Key Players:** Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), NeuroPace (US), St. Jude Medical (US), Stryker Corporation (US), Bioness (US), Horizon Therapeutics (IE) **Report ID:** MRFR/HC/10578-HCR · **Pages:** 87 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/freeze-of-gait-market-12099 --- ## Market Summary ## **Global Freeze of Gait Market Overview** Freeze of Gait Market size was valued at USD 1.19 billion in 2022. The Freeze of Gait market industry is projected to grow from USD 1.22 Billion in 2023 to USD 1.99 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.86% during the forecast period (2023 - 2032). The Increasing prevalence of freeze of gait is one of the major driving factors for market growth. ## **Freeze of Gait Market Trends** ### **Increasing prevalence of Parkinson’s disease and other related diseases** [Parkinson's disease](../../../reports/parkinsons-disease-therapeutics-market-1572) is a disorder of the central nervous system that causes unintended or uncontrollable movements, such as stiffness, shaking, and difficulty with coordination and balance. These symptoms generally begin slowly and worsen over time. This may result in difficulty walking and talking. Freezing of gait (FoG) is one of the most debilitating motor symptoms in Parkinson's disease (PD) patients. Freezing of gait is an abnormal gait pattern that leads to a sudden inability to initiate or continue walking. According to data published in Nature Journal, in the year 2022, FoG affected about 50% of Parkinson's disease patients and 80% of advanced Parkinson's disease patients. According to the Parkinson’s Foundation, currently around one million people in the US are living with Parkinson's disease (PD), and it is estimated that this number will rise to 1.2 million by 2030. ## **Freeze of Gait Market Segment Insights** ### **Freeze of Gait Type Insights** The Freeze of Gait Market segmentation, based on type, includes oral dopaminergic medication, wearable and walking aid devices, deep brain stimulation, and others. The wearable and walking aid devices segment is to hold the majority share in 2022 in the Freeze of Gait Market revenue due to easy to use, increasing disability case across the globe as well as increasing cases on uncontrollable moments are raise the demand of wearable and walking aid devices. Wearable and walking devices easily track the patient’s health and technological advancement in wearable and walking devices are further drive the growth of this segment. **October 2021:**Teva collaborated with MODAG for licensing and development of neurodegenerative disease drug candidate. This collaboration enhances the company’s product portfolio and business in the market. ### **Freeze of Gait End User Insights** The Freeze of Gait Market segmentation is based on end user that includes hospitals, clinics, others. The hospitals segment has dominated the market in 2022 due to the easy accessibility, growing cases of advanced Parkinson disease, expansion of muscle disorder treatment capability. Furthermore, availability of advanced treatment facilities, proficient [medical staff](../../../reports/healthcare-staffing-market-12278) and rising patient pool are driving the growth of this segment in freeze of gait market. **November 2020:** MedEXO Robotics, a Hong Kong-based robotics technology company had newly launched the ExoBeam walking device to relief patient with Parkinson’s disease and other movement disorders. **Figure 2: FREEZE OF GAIT MARKET, BY END USER, 2022 & 2032 (USD BILLION)** Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review ### **Freeze of Gait Regional Insights** By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. The North America Freeze of Gait market is expected to account for USD 0.48 billion in 2022 and is expected to exhibit a 5.17% CAGR during the study period. This is attributed to the business presence of major key player, rising FDA approval, and increasing awareness about the medication and therapies, rising prevalence of Parkinson disease in the region drive the regional market growth during the forecast period. In 2022, as per the Parkinson's Foundation, an estimated 90,000 suffered from Parkinson disease in the US people are affected by Freeze of Gait in the US, and this denotes a steep 50% growth from the earlier estimated rate of 60,000 diagnoses annually which is contributing to market growth over the forecast period. Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 3: GLOBAL FREEZE OF GAIT SHARE (%) BY REGION 2022** Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review Europe Freeze of Gait market is expected to account for the second-largest market share due to the increasing healthcare expenditure, rising demand for advanced therapeutics, and increasing geriatric population lead to risk of Parkinson disease associated freeze of gait which drive the growth of freeze gait in Europe region. Accessibility to advanced technology for disease diagnosis, the rising geriatric population prone to Freeze of Gait is driving up demand for effective treatment & therapeutics and increasing awareness about the freeze of gait. For instance, At present time more than 1.2 million people suffering from Parkinson’s in Europe and this number is forecast to double by 2030. In addition, The cost per Parkinson’s patient amounts to approximately USD 12,058 on average across Europe, and a cost to Europe of USD 15.24 billion annually Thus, increasing treatment cost per patient in Europe, rising research and development activity positively impact on the growth of freeze of gait market. Additionally,  favorable government support for better treatment facility are boosting the growth of the Freeze of Gait market in Europe. The Asia-Pacific freeze of gait market is expected to grow at a CAGR of 6.03% from 2023 to 2032. This is due to factors such as rising medical facility, increasing government initiative for freeze gait treatment, presence of large patient pool of Parkinson disease associated with freeze of gait are positively impact on the growth of freeze of gait market in Asia-Pacific region. Furthermore, availability of cheap labour cost, increasing interest of major key players for investment in Asia-Pacific region are further drive the growth of this market. The Rest of the World includes the Middle East, Africa, and Latin America. Middle East hold the major market share in middle east and Africa region due to rising government support for business establishment of key players, rising incidence of freeze of gait limited increasing number of research companies and subsidiaries involved in R&D, and increasing initiatives are taken by Middle East countries to develop their healthcare infrastructure. Moreover, growing awareness and demand from the general population for effective treatments are likely to favor market growth. ## **Freeze of Gait Key Market Players & Competitive Insights** The freeze of gait market is distinguished by the presence of numerous global, regional, and local players catering to the increasing research funding and collaborations, and growing Parkinson’s diseases. Because of increased adoption of advanced medical technologies and continuous development by companies, the freeze of gait market is becoming more profitable. Several factors are driving market growth, including increasing prevalence of Parkinson’s disease and other related diseases, the growing geriatric population, and increasing investment in R&D. Furthermore, the freeze of gait market is highly competitive, with players competing, collaborating, and investing heavily in research and development to gain a significant market share. The market is expanding with rising investment by key players. The growth of key market players is dependent on market conditions, government support, and industry development.  Key players in the Freeze of Gait Market focus on expanding regionally and improving their product quality and delivery. Although international players dominate the market, regional players with small market shares also have a considerable presence. The international players may strengthen their presence through acquisitions and collaborative agreements during the forecast period. It has also been forecasted that improvement of the global economic scenario combined with efforts to enhance product delivery globally is fueling the market growth, thereby making it an ideal time for new players with innovative products to enter the market and increase the market share. The market is moderately fragmented due to rising competition, product launches, increased collaborative partnerships, and other strategic decisions to achieve operational efficiency. ### **Key Companies in the Freeze of Gait Market Include** - Teva Pharmaceuticals (Israel) - Sun Pharmaceutical Industries Ltd (India) - Viatris Inc (US) - Gondola Medical Technologies SA (Switzerland) - Gyenno Technologies Co., Ltd. (China) - Beats Medical Limited (Ireland) - Agilitas (Australia) - Walk with Path (Vesterbro) - [MedEXO Robotics](https://www.medexorobotics.com/#gait) (Hong Kong) - Ustep (US) ## **Freeze of Gait Industry Developments** **October 2021**: Teva collaborated with MODAG for licensing and development of neurodegenerative disease drug candidate. This collaboration enhances the company’s product portfolio and business in the market. **September 2021**: Gondola Medical Technologies collaborated with Mount Sinai Health System (US) to enhance the scientific understanding of Automated Peripheral Mechanical Stimulation (AMPS) therapy. ## **Freeze of Gait Market Segmentation** ### **Freeze of Gait Type Outlook** - Oral Dopaminergic Medication - Wearable and Walking Aid Devices - Deep Brain Stimulation - Others ### **Freeze of Gait End User Outlook** - Hospitals - Clinics - Others ### **Freeze of Gait Regional Outlook** ## Market Drivers ### Growing Demand for Rehabilitation Services The demand for rehabilitation services tailored to individuals with movement disorders is on the rise, serving as a crucial driver for the Freeze of Gait Market. As awareness of the importance of rehabilitation in managing gait freezing increases, more patients are seeking specialized care. Rehabilitation programs that incorporate physical therapy, occupational therapy, and gait training are becoming essential components of treatment plans. Recent data indicates that rehabilitation services for movement disorders are expected to expand at a rate of approximately 10% annually. This growth is fueled by the recognition that comprehensive rehabilitation can significantly enhance mobility and quality of life for affected individuals. Consequently, healthcare providers are investing in developing specialized rehabilitation programs, thereby contributing to the overall growth of the Freeze of Gait Market. The emphasis on holistic care approaches is likely to further drive this trend. ### Rising Awareness and Education Initiatives Rising awareness and education initiatives regarding movement disorders are playing a pivotal role in shaping the Freeze of Gait Market. Increased efforts by healthcare organizations and advocacy groups to educate patients, families, and healthcare professionals about gait freezing are fostering a more informed public. These initiatives aim to highlight the challenges faced by individuals with movement disorders and the importance of early intervention. As awareness grows, so does the demand for effective treatment options and support services. Recent surveys indicate that nearly 70% of caregivers report a lack of knowledge about managing gait freezing, underscoring the need for targeted educational programs. This growing awareness is likely to drive the demand for specialized therapies and assistive devices, thereby propelling the Freeze of Gait Market forward. Enhanced education efforts may also lead to improved patient outcomes and satisfaction. ### Increasing Prevalence of Parkinsons Disease The rising incidence of Parkinson's disease is a primary driver for the Freeze of Gait Market. As this neurodegenerative disorder affects millions worldwide, the demand for effective treatment options is escalating. According to recent estimates, approximately 10 million individuals are living with Parkinsons disease, with a significant portion experiencing gait freezing episodes. This condition not only impacts mobility but also increases the risk of falls, leading to severe complications. Consequently, healthcare providers are focusing on developing innovative therapies and assistive devices tailored to manage these symptoms. The growing patient population necessitates a robust market response, thereby propelling advancements in the Freeze of Gait Market. Furthermore, the increasing awareness among caregivers and healthcare professionals about the implications of gait freezing is likely to enhance the demand for specialized interventions. ### Technological Innovations in Therapeutic Devices Technological advancements in therapeutic devices are significantly influencing the Freeze of Gait Market. Innovations such as wearable sensors, smart walking aids, and [neurostimulation devices](https://www.marketresearchfuture.com/reports/neurostimulation-devices-market-2263) are being developed to assist individuals experiencing gait freezing. These devices not only provide real-time feedback but also enhance mobility and safety for patients. For instance, the integration of artificial intelligence in gait analysis is enabling more personalized treatment approaches. The market for these devices is projected to grow substantially, with estimates suggesting a compound annual growth rate of over 15% in the coming years. This surge is attributed to the increasing investment in research and development aimed at creating more effective solutions for gait-related issues. As technology continues to evolve, the Freeze of Gait Market is likely to witness a transformation in how these conditions are managed, ultimately improving patient outcomes. ### Aging Population and Associated Health Challenges The aging population is a significant driver of the Freeze of Gait Market, as older adults are more susceptible to movement disorders, including gait freezing. As life expectancy increases, the number of elderly individuals experiencing mobility issues is also rising. It is estimated that by 2030, the global population aged 65 and older will reach approximately 1.5 billion, with a substantial proportion likely to face challenges related to gait. This demographic shift necessitates the development of targeted interventions and support systems to address the unique needs of older adults. Healthcare systems are increasingly recognizing the importance of addressing gait-related issues in this population, leading to a surge in research and development efforts. Consequently, the Freeze of Gait Market is expected to expand as healthcare providers seek to implement effective solutions for managing gait freezing in the aging population. ## Future Outlook The Freeze of Gait Market is projected to grow at a 4.86% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising geriatric populations. **New opportunities:** - Development of wearable gait monitoring devices for real-time feedback. Expansion of telehealth services for remote gait assessment. Partnerships with rehabilitation centers for integrated gait therapy solutions. By 2035, the Freeze of Gait Market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Oral Dopaminergic Medication (Largest) vs. Wearable and Walking Aid Devices (Fastest-Growing) In the Freeze of Gait Market, the distribution of share among segment values is notably diverse. Oral dopaminergic medication remains the largest segment, capturing the attention of both healthcare providers and patients due to its established efficacy in managing movement disorders. On the other hand, wearable and walking aid devices are rapidly gaining ground, as advancements in technology enhance their functionality and comfort for users. These segments are complemented by deep brain stimulation and other innovative treatments, each contributing significantly to the overall market dynamics. Growth trends within this segment reveal a robust increase in the adoption of wearable devices, driven by the aging population and increasing prevalence of gait-related disorders. As patients seek non-invasive options, wearable technologies are becoming vital for improving mobility and independence in daily activities. Simultaneously, the demand for oral dopaminergic medications continues to thrive, primarily fueled by growing awareness and accessibility. These trends indicate a market poised for substantial evolution in the coming years. Oral Dopaminergic Medication (Dominant) vs. Wearable and Walking Aid Devices (Emerging) The dominant segment, oral dopaminergic medication, has long been the cornerstone of treatment for individuals experiencing freeze of gait episodes. Its effectiveness stems from its ability to enhance dopaminergic activity in the brain, leading to improved mobility and reduced incidences of freezing. However, a notable emerging segment is wearable and walking aid devices, which offer innovative solutions to enhance patient mobility. These devices are now equipped with smart sensors, real-time data analytics, and personalized adjustments, making them increasingly valuable for those needing assistance. As both segments evolve, the demand for integrated treatment approaches that combine pharmacological and mechanical aids will likely pave the way for holistic management strategies within the Freeze of Gait Market. ### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the Freeze of Gait Market, hospitals account for the largest share among end users, reflecting their substantial role in the diagnosis and management of gait disorders. They are equipped with advanced technology and skilled professionals, making them a primary destination for patients seeking effective treatment. Clinics, while smaller in market share, represent the fastest-growing segment as they cater to a growing demand for outpatient services and offer specialized care for gait-related issues. Hospitals (Dominant) vs. Clinics (Emerging) Hospitals are the dominant end user in the Freeze of Gait Market due to their comprehensive facilities and resources. They provide a wide range of treatments and diagnostic tools, which are essential for managing complex gait disorders. In contrast, clinics represent an emerging segment, driven by increasing patient awareness and preference for convenient, localized care. Clinics often emphasize personalized treatment plans and accessibility, attracting patients looking for specialized care without the need for hospital admission. This dynamic highlights the shifting landscape of gait disorder management, where both hospitals and clinics play vital roles. ## Regional Market Share Analysis ### North America : Leading Innovation and Research North America is the largest market for Freeze of Gait Market solutions, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of Parkinson's disease, and significant investments in neurological research. Regulatory support from agencies like the FDA further catalyzes innovation and product approvals, enhancing market dynamics. The United States stands as the leading country, hosting major players such as Medtronic, Boston Scientific, and Abbott Laboratories. The competitive landscape is characterized by continuous technological advancements and strategic partnerships among key players. The presence of robust healthcare systems and a growing elderly population further fuels demand for effective treatment options in this sector. ### Europe : Emerging Regulatory Frameworks Europe is the second-largest market for Freeze of Gait Market solutions, holding around 30% of the global market share. The region's growth is propelled by an aging population, increasing awareness of neurological disorders, and supportive healthcare policies. Countries like Germany and France are leading the charge, with regulatory frameworks that encourage innovation and accessibility to advanced treatment options for patients suffering from gait disorders. Germany and France are at the forefront, with a strong presence of key players such as Horizon Therapeutics and other local manufacturers. The competitive landscape is marked by collaborations between healthcare providers and technology firms, aiming to enhance treatment efficacy. The European Medicines Agency plays a crucial role in ensuring that new therapies meet safety and efficacy standards, thereby fostering market growth. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is witnessing rapid growth in the Freeze of Gait Market, contributing approximately 15% to the global market share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of neurological disorders, and a growing elderly population. Countries like Japan and China are leading this growth, supported by government initiatives aimed at improving healthcare access and quality. Japan and China are the primary markets, with a mix of local and international players entering the landscape. The competitive environment is evolving, with companies focusing on innovative solutions tailored to regional needs. Collaborations between healthcare institutions and technology firms are becoming more common, enhancing the availability of effective treatments for gait disorders, thus driving market growth. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region represents a nascent market for Freeze of Gait Market solutions, holding about 10% of the global market share. The growth potential is significant, driven by increasing healthcare investments, rising awareness of neurological conditions, and a growing focus on improving healthcare infrastructure. Countries like South Africa and the UAE are beginning to recognize the importance of addressing gait disorders, leading to gradual market development. South Africa and the UAE are emerging as key players in this market, with local healthcare providers starting to collaborate with international firms. The competitive landscape is still developing, but there is a growing interest from The Freeze of Gait Market. As healthcare systems improve and awareness increases, the demand for effective treatments for gait disorders is expected to rise significantly. ## Competitive Benchmarking The freeze of gait market is distinguished by the presence of numerous global, regional, and local players catering to the increasing research funding and collaborations, and growing Parkinson’s diseases. Because of increased adoption of advanced medical technologies and continuous development by companies, the freeze of gait market is becoming more profitable. Several factors are driving market growth, including increasing prevalence of Parkinson’s disease and other related diseases, the growing geriatric population, and increasing investment in R&D. Furthermore, the freeze of gait market is highly competitive, with players competing, collaborating, and investing heavily in research and development to gain a significant market share. The market is expanding with rising investment by key players. The growth of key market players is dependent on market conditions, government support, and industry development.  Key players in the Freeze of Gait Market focus on expanding regionally and improving their product quality and delivery. Although international players dominate the market, regional players with small market shares also have a considerable presence. The international players may strengthen their presence through acquisitions and collaborative agreements during the forecast period. It has also been forecasted that improvement of the global economic scenario combined with efforts to enhance product delivery globally is fueling the market growth, thereby making it an ideal time for new players with innovative products to enter the market and increase the market share. The market is moderately fragmented due to rising competition, product launches, increased collaborative partnerships, and other strategic decisions to achieve operational efficiency. ## Recent News & Developments **October 2021**: Teva collaborated with MODAG for licensing and development of [neurodegenerative disease](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218) drug candidate. This collaboration enhances the company’s product portfolio and business in the market. **September 2021**: [Gondola](https://www.marketresearchfuture.com/reports/gondola-market-14044) Medical Technologies collaborated with Mount Sinai Health System (US) to enhance the scientific understanding of Automated Peripheral Mechanical Stimulation (AMPS) therapy. ## Report Scope | MARKET SIZE 2024 | 1.279(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.341(USD Billion) | | MARKET SIZE 2035 | 2.156(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.86% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), NeuroPace (US), St. Jude Medical (US), Stryker Corporation (US), Bioness (US), Horizon Therapeutics (IE) | | Segments Covered | Type | | Key Market Opportunities | Advancements in wearable technology enhance management solutions in the Freeze of Gait Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and technological advancements in the Freeze of Gait Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Freeze of Gait Market?** A: As of 2024, the Freeze of Gait Market was valued at 1.279 USD Billion. **Q: What is the projected market valuation for the Freeze of Gait Market in 2035?** A: The Freeze of Gait Market is projected to reach 2.156 USD Billion by 2035. **Q: What is the expected CAGR for the Freeze of Gait Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Freeze of Gait Market from 2025 to 2035 is 4.86%. **Q: Which companies are the key players in the Freeze of Gait Market?** A: Key players in the Freeze of Gait Market include Medtronic, Boston Scientific, Abbott Laboratories, and others. **Q: What are the main segments of the Freeze of Gait Market?** A: The main segments of the Freeze of Gait Market include Oral Dopaminergic Medication, Wearable and Walking Aid Devices, and Deep Brain Stimulation. **Q: How did the Oral Dopaminergic Medication segment perform in 2024?** A: In 2024, the Oral Dopaminergic Medication segment was valued at 0.4 USD Billion and is expected to grow to 0.65 USD Billion. **Q: What is the valuation of the Wearable and Walking Aid Devices segment?** A: The Wearable and Walking Aid Devices segment was valued at 0.35 USD Billion in 2024 and is projected to reach 0.6 USD Billion. **Q: What is the market size for hospitals as an end user in the Freeze of Gait Market?** A: In 2024, hospitals accounted for a market size of 0.511 USD Billion, with projections of reaching 0.883 USD Billion. **Q: How does the market for clinics compare to other end users?** A: The clinic segment was valued at 0.384 USD Billion in 2024 and is expected to grow to 0.646 USD Billion. **Q: What are the growth prospects for the 'Others' segment in the Freeze of Gait Market?** A: The 'Others' segment was valued at 0.229 USD Billion in 2024 and is projected to increase to 0.406 USD Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/freeze-of-gait-market-12099*